Merck & Co., Inc. vs Public Storage — how do they compare? Merck & Co., Inc. trades at $130.21 (market cap $323.00B), while Public Storage trades at $324.41 (market cap $60.82B). The key difference: Merck & Co., Inc. is far larger — about 5.3× Public Storage's market cap, and Public Storage pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| MRK | PSA | |
|---|---|---|
Market Cap | $323.00B | $60.82B |
Sector | Health | Real Estate |
52-Week High | $131.84 | $330.47 |
52-Week Low | $77.60 | $258.44 |
Enterprise Value | $369.77B | $75.10B |
Dividend Yield | 2.6% | 3.68% |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Public Storage (PSA) trades at $328.40, up 0.43% on the day, with a bullish technical signal from moving averages and a consensus price target of $333.88. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised full-year guidance following the acquisition of National Storage Affiliates. Strong profitability is evident with a net income margin of 41.8% and ROE of 37.42%, though valuation multiples like P/E of 31.34 suggest a premium.
Outlook remains positive due to accretive acquisitions and dividend stability, with a $3.00 quarterly dividend declared. Risks include high valuation, interest rate sensitivity, and integration challenges from recent deals. Analyst sentiment is mixed with 28.6% buy ratings, but institutional activity shows both position increases and cuts, indicating cautious optimism.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →